治療藥監測市場:目前分析與預測(2022-20230年)

Therapeutic Drug Monitoring Market: Current Analysis and Forecast (2022-20230)

出版日期: 2023年05月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 2022 年至 2030 年治療藥物監測市場的複合年增長率將達到 10% 左右。治療藥物監測 (TDM) 測量患者血液和其他體液中的藥物濃度，以最大限度地提高藥物治療的功效和安全性。TDM 的目的是確保患者根據個人特徵（如年齡、體重、遺傳和其他醫療問題）接受正確的藥物劑量。TDM常用於治療窗較窄的藥物，即藥物的最低有效濃度與其危險濃度之間差距較小的藥物。通過監測藥物濃度，醫療保健專業人員可以改變實現治療效果所需的劑量和頻率，從而最大限度地降低副作用的風險。全球癌症、糖尿病和心髒病等慢性疾病的患病率不斷上升，推動了對治療藥物監測的需求不斷增長。例如，根據疾病預防控制中心的數據，大約有1800萬20歲以上的美國人患有心髒病，每年有近65萬人死於心髒病。這些統計數據表明，治療藥物監測有助於減少和優化需要長期藥物治療的慢性病患者的藥物治療，例如癌症、糖尿病和心血管疾病，並將有助於未來的市場增長。為發展做出貢獻此外，由於醫療保健專業人員的意識不斷增強，治療藥物監測市場預計將增長。然而，設備成本高、監管嚴格等市場製約因素正在阻礙全球市場的增長。

治療藥物監測在北美越來越受歡迎。癌症等慢性病患病率的不斷上升正在推動該地區治療藥物監測市場的需求。對個性化醫療不斷增長的需求是 TDM 的一個亮點，因為它使醫療保健提供者能夠根據患者特定的藥代動力學和藥效學特徵為個體患者量身定製藥物治療。技術進步也促進了治療藥物監測市場的增長。例如，2020年6月，Quest Diagnostics推出了針對免疫抑製劑黴酚酸的新治療藥物監測測試。政府不斷加大推廣 TDM 的力度，進一步推動了該地區市場的增長。

The therapeutic drug monitoring market is expected to register a CAGR of approx. 10% over the period of 2022-2030. Therapeutic drug monitoring (TDM) measures drug concentrations in a patient's blood or other bodily fluids to maximize the efficacy and security of pharmacological therapy. TDM's purpose is to guarantee that a patient receives the correct medicine dose depending on individual characteristics such as age, weight, genetics, and other medical problems. TDM is commonly employed for medications with a narrow therapeutic range, which means there is a tiny gap between the drug's minimum effective concentration and hazardous concentration. Healthcare practitioners can alter the amount or frequency of delivery as needed to achieve the intended therapeutic benefit while minimizing the risk of unwanted effects by monitoring medication levels. The growing demand for therapeutic drug monitoring can be attributed to the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. across the globe. For instance, according to the CDC, around 18 million Americans aged 20 and above have heart disease and nearly 650,000 Americans die of heart disease each year. Owing to the glaring statistics therapeutic drug monitoring help to reduce or optimize drug therapy in the patient suffering from chronic diseases such as cancer, diabetes, and cardiovascular disease, etc. which require long-term drug therapy which would contribute to the growth of the market in the forthcoming period as well. Furthermore, the therapeutic drug monitoring market is anticipated to grow on account of the increasing awareness among healthcare professionals. However, some of the restraints in the market, including the high cost of the equipment and stringent regulations are impeding the growth of this market all over the world.

Based on product type, the market is segmented into consumables and devices. Among them, the consumables segment captured a significant share of the market in 2021. This is due to the increasing prevalence of chronic diseases which is boosting this segment. Moreover, the increasing demand for new technology-based, cost-effective kits and the use of reagents in the R&D area is also boosting the growth of the segment of the market.

Based on the technology, the market is bifurcated into immunoassays, proteomic technologies, and others. Among them, the immunoassays segment is expected to grow at a higher CAGR in the market. This is due to the availability of highly specific and reliable immunoassay which is likely to aid the growth of the segment. Moreover, the rising adoption rate of advanced techniques and the requirement of minimal training to handle the equipment also boosted the growth of the segment.

Based on the drug class, the therapeutic drug monitoring market has been classified as anti-epileptics, antibiotics, immunosuppressants, psychoactive, and anti-arrhythmic drugs. Among them, the anti-epileptics category grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. The increasing prevalence of epilepsy and seizures are the factors that help in boosting the segment. Moreover, the rising growth in the number of Anti-epileptic drugs is also likely to aid the segment growth.

Based on the end-user, the therapeutic drug monitoring market has been classified as hospital labs, private labs, and others. Among them, the hospital labs segment is expected to grow at a higher CAGR in the market. This is due to the availability of accurate patient information, such as age, metabolism, ethnicity, and drug performance history in the hospitals which boost the segment growth. Moreover, the increasing use of computerized entry of patient history and information records is more likely to boost the growth of the market segment.

For a better understanding of the market adoption of therapeutic drug monitoring, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. Therapeutic drug monitoring has gained increasing popularity in North America due to various factors. The increasing prevalence of chronic diseases such as cancer, etc. is boosting the demand for the therapeutic drug monitoring market in this region. The growing demand for personalized medicine is becoming the highlight for TDM as it allows healthcare providers to tailor drug therapy to individual patients based on their unique pharmacokinetic and pharmacodynamics profiles. The advancement in technology is also attributed to the growth of the therapeutic drug monitoring market. For instance, In June 2020, Quest Diagnostics launched a new therapeutic drug monitoring test for the immunosuppressive drug, Mycophenolic Acid. Increasing government initiatives to promote TDM further boosted the growth of the market in the region.

Some of the major players operating: Roche AG, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMerieux, Inc., Bayer AG, Alere, Inc among others. Several M&A's along with partnerships have been undertaken.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Therapeutic Drug Monitoring Market
2.2. Research Methodology of the Therapeutic Drug Monitoring Market
2.4. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE THERAPEUTIC DRUG MONITORING MARKET

6 GLOBAL THERAPEUTIC DRUG MONITORING MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

7.1. Consumables
7.2. Devices

8 MARKET INSIGHTS BY TECHNOLOGY

8.1. Immunoassays
8.2. Proteomic Technologies
8.3. Others

9 MARKET INSIGHTS BY DRUG CLASS

9.1. Anti-Epileptics
9.2. Antibiotics
9.3. Immunosuppressants
9.4. Psychoactive
9.5. Anti-Arrhythmic Drugs

10 MARKET INSIGHTS BY END-USER

10.1. Hospital Labs
10.2. Private Labs
10.3. Others

11 MARKET INSIGHTS BY REGION

11.1 NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Rest of North America
11.2 EUROPE THERAPEUTIC DRUG MONITORING MARKET
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 United Kingdom
- 11.2.4 Spain
- 11.2.5 Italy
- 11.2.6 Rest of Europe
11.3 ASIA PACIFIC THERAPEUTIC DRUG MONITORING MARKET
- 11.3.1 China
- 11.3.2 Japan
- 11.3.3 India
- 11.3.4 Rest of Asia Pacific
11.4 REST OF THE WORLD THERAPEUTIC DRUG MONITORING MARKET